Lophophine
Lophophine (also known as MMDPEA and 3-Methoxy-4,5-methylenedioxyphenethylamine) is a putative psychedelic and entactogen drug of the phenethylamine class. It is the methoxy analog of MDPEA and is also more distantly related to mescaline.
History[edit]
Lophophine was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines I Have Known And Loved), the dosage is listed as 150-250 mg, and the duration is listed as 6–8 hours. Shulgin reports that lophophine has a unique property among psychedelics: it does not induce the visual effects typically associated with other psychedelic drugs.
Pharmacology[edit]
The pharmacology of lophophine is not well known, but it is likely to act by increasing levels of serotonin, dopamine, and norepinephrine in the brain. It may also act on the serotonin receptors, specifically the 5-HT2A receptor, which is known to be responsible for the effects of many psychedelic drugs.
Legal Status[edit]
Lophophine is not controlled in the United States and is therefore legal to buy, possess, and sell. However, it could potentially be considered an analog of a Schedule I drug under the Federal Analogue Act if it is intended for human consumption.
See Also[edit]
| Psychoactive drugs | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This psychoactive drug related article is a stub.
|
